Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. He has also been selected by Martindale-Hubbell as a 2017-2021 Top Rated Lawyer. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report. The FDA approved Sanofi SA's (NASDAQ:SNY) licensure request for influenza vaccine approval for the upcoming 2022-2023 flu season, including Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, and Fluzone Quadrivalent.We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. Sanofi's Flu Vaccines Included In CDC Preferred Higher-Dose Vaccines For 65 Years & Above
Median progression-free survival was 8.2 months, and median overall survival was 24.1 months. The median duration of response in these patients was 12.4 months.
#Tyme technologies news full#
Seagen Inc (NASDAQ:SGEN) announced full results from the phase 2 MOUNTAINEER trial, which showed Tukysa (tucatinib) combined with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer.Īt a median duration of follow-up of 20.7 months, the data showed a 38.1% confirmed objective response rate in Tukysa plus trastuzumab combo regime. Seagen's Tucatinib Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer TYME shares are up 42.3% at 38 cents during the premarket session. TYME stockholders are expected to receive approximately 0.4312 shares of Syros shares for each share of TYME share. Syros expects to issue approximately 74.3 million shares. Syros Pharmaceuticals Inc (NASDAQ:SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ:TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million.
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma AstraZeneca will make additional contingent R&D-related milestone payments of up to $805 million and additional contingent commercial-related milestone payments of up to $360 million to TeneoTwo's equity holders. Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca Strengthens Its Hematological Cancer Pipeline With TeneoTwo AcquisitionĪstraZeneca Plc (NASDAQ:AZN) has agreed to acquire TeneoTwo, Inc, including its Phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.ĭeal consideration includes an upfront payment of $100 million.
0 kommentar(er)
